NCT04387734View on ClinicalTrials.gov

Effects of Ocrevus in Relapsing Multiple Sclerosis

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 5, 2021

Primary Completion Date

February 17, 2025

Study Completion Date

September 30, 2025

Conditions
Relapsing Multiple Sclerosis
Interventions
DRUG

Ocrelizumab

Ocrevus will be administered following the FDA's regulations.

DRUG

Platform

The applications of the platform DMTs will follow the FDA-approved regulations.

Trial Locations (2)

30303

Georgia State University, Atlanta

30327

Multiple Sclerosis Center of Atlanta, Atlanta

All Listed Sponsors
collaborator

Multiple Sclerosis Center of Atlanta

OTHER

lead

Georgia State University

OTHER